Docetaxel and Oxaliplatin in the Second-Line Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II Study
August 2007
in “
Annals of Oncology
”
TLDR Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.
In a phase II study from October 2003 to June 2006, 43 patients with platinum-sensitive recurrent ovarian cancer were treated with a combination of docetaxel (DTX) and oxaliplatin (OXA) after a platinum-free interval of more than 12 months. The treatment regimen resulted in an overall response rate of 67.4%, with 17 complete and 12 partial responses. The median duration of response was 10 months, median time to progression was 14 months, and overall survival was 28 months. The toxicity profile was favorable, with 32.5% of patients experiencing grade 3-4 leukopenia, 9.3% with grade 3-4 neurotoxicity, and 34.9% with grade 2 alopecia. The study concluded that the DTX/OXA combination is an effective treatment with manageable side effects for patients with recurrent platinum-sensitive ovarian cancer.